Vidaillac C, Parra-Ruiz J, Rybak MJ. In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin.
Diagn Microbiol Infect Dis 2011;
71:470-3. [PMID:
22018937 DOI:
10.1016/j.diagmicrobio.2011.09.002]
[Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2011] [Revised: 08/29/2011] [Accepted: 09/02/2011] [Indexed: 01/22/2023]
Abstract
Oritavancin exhibited lower MIC(50) values (0.03 and 0.5 mg/L) than comparators against methicillin-resistant Staphylococcus aureus (MRSA, n = 50) and vancomycin-intermediate SA strains (n = 60). At subtherapeutic concentrations, oritavancin demonstrated rapid (within 9 h) and concentration-dependent bactericidal activity against daptomycin nonsusceptible (DNS) MRSA. Further investigations are warranted to determine the therapeutic potential of oritavancin against DNS MRSA.
Collapse